Josiah Zayner cursed under his breath as blood pooled under the thin skin of his subject’s leg. He checked for vital signs: no breathing.
“I think I might have got the vein on that one accidentally,” he said.
Zayner, who had just administered an experimental injection, has a doctorate in biochemistry and biophysics from the University of Chicago, but to his patient such credentials were meaningless.
The leg in question belonged to a Hyla cinerea, a small green tree frog not more than two inches long. The idea was to inject a genetic cocktail to make the frog’s muscles grow larger.
A few hours later, the frog was back to its usually hoppy self, but it was touch-and-go for a while.
A year earlier, that gushing blood could have been Zayner’s own. He has garnered attention and headlines for administering experiments in a kind of performance-art-meets-biohacking theatric for a live audience and those watching on YouTube.
He once invited a reporter to witness a self-administered fecal implant to treat an irritable stomach; the procedure entailed swallowing a pill filled with a friend’s poop.
He attempted to genetically modify his skin cells to turn a patch a darker color. As he did to the frog, he has also injected himself with a DNA mix in a bid to bulk up his muscles. Should one feel inspired to recreate some of Zayner’s antics at home, he will sell you the tools to do so on his company Web site, The Odin.
Is this Silicon Valley’s answer to vaudeville? Or is Zayner at the forefront of a movement in which biotech is trickling down to garage entrepreneurs, in the same way that democratized computer and coding technology let curious tinkerers build Silicon Valley?
For now, Zayner has turned his attention to critters, after the US Food and Drug Administration issued a warning on the sale of gene-therapy products for DIY human use.
For US$499, anyone can order a kit containing six frogs, cages, food and all the materials necessary to replicate Zayner’s frog muscle therapy at home.
Zayner believes the experiment is legal: The US Animal Welfare Act exempts “cold-blooded” animals, including frogs, which the FDA regards as a “minor” species anyway.
Maybe not minor enough, though, after their DNA has been altered.
“The FDA does not regulate the kits you mention. However, the agency does regulate animals that contain intentionally altered genomic DNA,” an FDA spokesperson said.
The kits are the fruit of six months of experiments at Zayner’s West Oakland, California, laboratory, which houses dozens upon dozens of tree frogs — Zayner is not sure exactly how many.
The lab is a sophisticated, albeit less-than-sterile, space with an office fridge stocked with Red Bull and coconut water. His three full-time employees tap away on laptops filling orders, answering customer inquiries and helping design instruction materials. A big-screen TV livestreams a computer game competition. His younger brother lives upstairs.
Despite his body piercings and disdain for the slow pace of institutional science, Zayner has garnered a surprising amount of respect from the establishment. He is regularly asked to speak at conferences.
Last year, the famous Harvard University geneticist George Church signed on as an adviser to Zayner’s company. Church believes DIY bio is part of a long evolution of human activity that has culminated with rapid advancements in scientific fields such as genetics.
“DIY bio is a modern extension of ancient practices like breeding plants, animals [and] microbes,” Church said.
Zayner said that he wants to democratize science, helping people understand today’s technologies and make the most of what modern medicine has to offer.
He can veer toward grandiosity, having once prophesied a world where people would cure whatever ails them through their own genetic experimentation, or toy around with DNA recreationally.
“I don’t want to say I want to, like, take down the FDA, but we need to figure out a new model that works,” Zayner said, right before injecting the frogs with their first round of follistatin.
“There are a tonne of people dying and suffering that don’t have access to the drugs they need. Something is going to have to break eventually, right? I don’t know when and I don’t know what’s going to cause it, but maybe we can help push things forward,” he said.
After Zayner’s first public injection, a young, HIV-positive software engineer gave himself a vaccine meant to suppress HIV while streaming the endeavor on Facebook Live.
In February, Aaron Traywick, chief executive officer of a biotech start-up developing its own treatments outside the purview of regulators, announced onstage at a body-hacking conference that he had herpes, then took off his pants and injected his thigh with a “gene therapy” he claimed could both prevent and cure the virus.
Traywick’s death a few months later was unrelated to that or any DIY procedure; he drowned in a sensory-deprivation tank with ketamine in his system.
“[The] FDA is aware that gene therapy products intended for self-administration and do-it-yourself kits to produce gene therapies for self-administration are being made available to the public. The sale of these products is against the law. FDA is concerned about the safety risks involved,” the agency said in the warning.
Thus the pivot to amphibians.
Zayner says the evidence suggests they should work well for the tests. In one experiment he conducted, 12 frogs were given a different DNA mixture containing IGF-1, a human growth factor he hopes would make the frogs grow bigger than usual.
After several injections and a few weeks, their weight on average increased by about 23 percent. Six untreated frogs gained hardly any weight at all. Tests revealed that the DNA was in the frog’s liver, a sign the animal’s body was reproducing it.
Could Zayner’s frog experiments ever translate into safe DIY gene therapies for humans? Medical experts are not yet convinced.
“The idea that a homebrew guy could inject a frog and deduce whether the same therapy would work in a person” is a stretch, Stanford bioethicist Hank Greely said. “If this is a step toward successful DIY gene therapy, it is a very small step on a very long path.”
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
United Microelectronics Corp (UMC, 聯電) forecast that its wafer shipments this quarter would grow up to 7 percent sequentially and the factory utilization rate would rise to 75 percent, indicating that customers did not alter their ordering behavior due to the US President Donald Trump’s capricious US tariff policies. However, the uncertainty about US tariffs has weighed on the chipmaker’s business visibility for the second half of this year, UMC chief financial officer Liu Chi-tung (劉啟東) said at an online earnings conference yesterday. “Although the escalating trade tensions and global tariff policies have increased uncertainty in the semiconductor industry, we have not
Intel Corp has named Tasha Chuang (莊蓓瑜) to lead Intel Taiwan in a bid to reinforce relations between the company and its Taiwanese partners. The appointment of Chuang as general manager for Intel Taiwan takes effect on Thursday, the firm said in a statement yesterday. Chuang is to lead her team in Taiwan to pursue product development and sales growth in an effort to reinforce the company’s ties with its partners and clients, Intel said. Chuang was previously in charge of managing Intel’s ties with leading Taiwanese PC brand Asustek Computer Inc (華碩), which included helping Asustek strengthen its global businesses, the company
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new